These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 20126852)

  • 1. Evaluation of late-onset hypogonadism (andropause) treatment using three different formulations of injectable testosterone.
    Hohl A; Marques MO; Coral MH; Walz R
    Arq Bras Endocrinol Metabol; 2009 Nov; 53(8):989-95. PubMed ID: 20126852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
    Moon DG; Park MG; Lee SW; Park K; Park JK; Kim SW; Park NC; Ahn TY; Paick JS; Seo JT; Yang DY; Lee JY; Kim JJ
    J Sex Med; 2010 Jun; 7(6):2253-2260. PubMed ID: 20345732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Nebido in the treatment of hypogonadism syndrome and its complications in men].
    Dedov II; Kurbatov DG; Rozhivanov RV; Lepetukhin AE; Dubskiĭ SA; Goncharov NP
    Urologiia; 2011; (6):59-60, 62-7. PubMed ID: 22448484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone therapy--what, when and to whom?
    Jockenhövel F
    Aging Male; 2004 Dec; 7(4):319-24. PubMed ID: 15799128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
    Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
    J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone replacement therapy in reversing "andropause": what is the proof-of-principle?
    Lang PO; Samaras D; Samaras N
    Rejuvenation Res; 2012 Oct; 15(5):453-65. PubMed ID: 22656862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
    Morrison BF; Reid M; Madden W; Burnett AL
    Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of androgen substitution on lipid profile in the adult and aging hypogonadal male.
    Schleich F; Legros JJ
    Eur J Endocrinol; 2004 Oct; 151(4):415-24. PubMed ID: 15476438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Testosterone substitution with special regard to prostate cancer].
    Beintker M; Behre H
    Urologe A; 2008 Dec; 47(12):1588-91. PubMed ID: 18931991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Andropause].
    Hochreiter WW; Ackermann DK; Brütsch HP
    Ther Umsch; 2005 Dec; 62(12):821-6. PubMed ID: 16405287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone for 'late-onset hypogonadism' in men?
    Drug Ther Bull; 2010 Jun; 48(6):69-72. PubMed ID: 20530029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints.
    Permpongkosol S; Tantirangsee N; Ratana-olarn K
    J Sex Med; 2010 Nov; 7(11):3765-74. PubMed ID: 20807330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
    Moisey R; Swinburne J; Orme S
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normative hypogonadism and depression: Does 'andropause' exist?
    Seidman SN
    Int J Impot Res; 2006; 18(5):415-22. PubMed ID: 16395322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sleep disturbance as a clinical sign for severe hypogonadism: efficacy of testosterone replacement therapy on sleep disturbance among hypogonadal men without obstructive sleep apnea.
    Shigehara K; Konaka H; Sugimoto K; Nohara T; Izumi K; Kadono Y; Namiki M; Mizokami A
    Aging Male; 2018 Jun; 21(2):99-105. PubMed ID: 28920756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory diagnosis of late-onset male hypogonadism andropause.
    Clapauch R; Carmo AM; Marinheiro L; Buksman S; Pessoa I
    Arq Bras Endocrinol Metabol; 2008 Dec; 52(9):1430-8. PubMed ID: 19197450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unexpectedly prolonged washout period of exogenous testosterone after discontinuation of intramuscular testosterone undecanoate depot injection (Nebido(®) or Reandron(®) ) in men with congenital hypogonadotrophic hypogonadism.
    Gan EH; Bouloux PM; Quinton R
    Clin Endocrinol (Oxf); 2016 Jun; 84(6):947-50. PubMed ID: 26732131
    [No Abstract]   [Full Text] [Related]  

  • 19. [Role of androgen in the elderly. Clinical androgen replacement therapy for late-onset hypogonadism].
    Amano T
    Clin Calcium; 2013 Aug; 23(8):1179-84. PubMed ID: 23892219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The testosterone therapy in patients with andropause].
    Krysiak R; Okopień B; Gdula-Dymek A
    Wiad Lek; 2007; 60(7-8):356-64. PubMed ID: 18175556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.